David Lewis

3.1k total citations · 1 hit paper
39 papers, 546 citations indexed

About

David Lewis is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, David Lewis has authored 39 papers receiving a total of 546 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Pathology and Forensic Medicine, 21 papers in Genetics and 21 papers in Oncology. Recurrent topics in David Lewis's work include Lymphoma Diagnosis and Treatment (22 papers), Chronic Lymphocytic Leukemia Research (21 papers) and CAR-T cell therapy research (9 papers). David Lewis is often cited by papers focused on Lymphoma Diagnosis and Treatment (22 papers), Chronic Lymphocytic Leukemia Research (21 papers) and CAR-T cell therapy research (9 papers). David Lewis collaborates with scholars based in United Kingdom, United States and Italy. David Lewis's co-authors include Kim Linton, Pieternella J. Lugtenburg, Anna Sureda, Rogier Mous, David Cunningham, Martine E.D. Chamuleau, Brian Elliott, Martin Hutchings, Michael Roost Clausen and Dena DeMarco and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

David Lewis

36 papers receiving 535 citations

Hit Papers

Dose escalation of subcutaneous epcoritamab in patients w... 2021 2026 2022 2024 2021 50 100 150 200
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study
    2021 212 citations Martin Hutchings, Rogier Mous et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Lewis United Kingdom 12 388 354 138 120 103 39 546
Sumeet Ambarkhane United States 9 513 1.3× 439 1.2× 155 1.1× 155 1.3× 91 0.9× 41 654
Aleš Obr Czechia 8 384 1.0× 366 1.0× 125 0.9× 74 0.6× 80 0.8× 21 483
Gloria Iacoboni Spain 16 588 1.5× 294 0.8× 116 0.8× 111 0.9× 92 0.9× 65 730
Brian Hess United States 11 452 1.2× 354 1.0× 96 0.7× 122 1.0× 115 1.1× 53 597
Martin Dreyling Germany 13 344 0.9× 470 1.3× 226 1.6× 84 0.7× 66 0.6× 28 622
Zhitao Ying China 14 502 1.3× 382 1.1× 84 0.6× 171 1.4× 57 0.6× 73 797
Ranjit Nair United States 13 594 1.5× 269 0.8× 62 0.4× 113 0.9× 52 0.5× 97 723
Julien Lazarovici France 10 435 1.1× 335 0.9× 94 0.7× 189 1.6× 70 0.7× 36 684
Chaitra S. Ujjani United States 15 622 1.6× 487 1.4× 234 1.7× 156 1.3× 53 0.5× 92 855
M Pfreundschuh Germany 13 219 0.6× 235 0.7× 94 0.7× 179 1.5× 59 0.6× 33 489

Countries citing papers authored by David Lewis

Since Specialization
Citations

This map shows the geographic impact of David Lewis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Lewis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Lewis more than expected).

Fields of papers citing papers by David Lewis

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Lewis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Lewis. The network helps show where David Lewis may publish in the future.

Co-authorship network of co-authors of David Lewis

This figure shows the co-authorship network connecting the top 25 collaborators of David Lewis. A scholar is included among the top collaborators of David Lewis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Lewis. David Lewis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Martin, Anne Laure, Toby A. Eyre, Yen Ying Lim, et al.. (2025). 617 | INCIDENCE AND SURVIVAL OF MANTLE CELL LYMPHOMA IN ENGLAND 2014–2021: A NATIONAL COHORT STUDY FROM THE UNCOVER STUDY GROUP. Hematological Oncology. 43(S3).
2.
Brody, Joshua, Judit Jørgensen, David Belada, et al.. (2025). Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial. Blood. 145(15). 1621–1631. 12 indexed citations
3.
Gouill, Steven Le, Virginie De Wilde, Toby A. Eyre, et al.. (2024). Ibrutinib, Venetoclax Plus CD20 Monoclonal Ab Provides Very High MRD Negativity in Previously Untreated MCL Patients, Initial Results of OASIS II, a Randomized Phase 2 Trial. Blood. 144(Supplement 1). 745–745. 1 indexed citations
4.
Kothari, Jaimal, Toby A. Eyre, Ali Rismani, et al.. (2024). PembroWM : A phase II trial to investigate the safety and efficacy of rituximab and pembrolizumab in relapsed/refractory Waldenström's Macroglobulinaemia. British Journal of Haematology. 205(6). 2273–2281. 3 indexed citations
5.
Brody, Joshua, David Belada, Régis Costello, et al.. (2024). Subcutaneous epcoritamab + GemOx in patients with relapsed or refractory DLBCL: Updated results from EPCORE NHL-2.. Journal of Clinical Oncology. 42(16_suppl). 7037–7037. 3 indexed citations
6.
Linton, Kim, Francesco Forconi, David Lewis, et al.. (2023). Robust Bruton’s tyrosine kinase (BTK) degradation with NX‐5948, an oral BTK degrader, in a first‐in‐human phase 1a trial in relapsed/refractory B cell malignancies. Hematological Oncology. 41(S2). 573–574. 4 indexed citations
7.
Villa, Diego, Aixiang Jiang, Carlo Visco, et al.. (2023). Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed/refractory mantle cell lymphoma. Blood Advances. 7(16). 4576–4585. 11 indexed citations
8.
Wang, Michael, Nirav N. Shah, Wojciech Jurczak, et al.. (2023). MCL-155 Pirtobrutinib in Covalent BTK Inhibitor Pre-Treated Mantle Cell Lymphoma: Updated Results and Subgroup Analysis from the Phase 1/2 BRUIN Study With >3 Years Follow-Up from Start of Enrollment. Clinical Lymphoma Myeloma & Leukemia. 23. S459–S459. 1 indexed citations
9.
10.
Shah, Nirav N., Wojciech Jurczak, Pier Luigi Zinzani, et al.. (2023). Pirtobrutinib in covalent BTK-inhibitor (cBTKi) pre-treated mantle cell lymphoma (MCL): Updated results and subgroup analysis from the phase 1/2 BRUIN study with >3 years follow-up from start of enrollment.. Journal of Clinical Oncology. 41(16_suppl). 7514–7514. 1 indexed citations
11.
12.
Eyre, Toby A., Mark Bishton, Rory McCulloch, et al.. (2023). Diagnosis and management of mantle cell lymphoma: A British Society for Haematology Guideline. British Journal of Haematology. 204(1). 108–126. 10 indexed citations
13.
14.
15.
Hutchings, Martin, Rogier Mous, Michael Roost Clausen, et al.. (2021). Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study. The Lancet. 398(10306). 1157–1169. 212 indexed citations breakdown →
16.
Cioppa, Giovanni Della, Ingileif Jónsdóttir, & David Lewis. (2015). Challenges in early clinical development of adjuvanted vaccines. Vaccine. 33. B47–B51. 9 indexed citations
17.
Lewis, David, et al.. (2007). One to one interventions to reduce sexually transmitted infections and under the age of 18 conceptions: a systematic review of the economic evaluations. Sexually Transmitted Infections. 83(6). 441–446. 13 indexed citations
18.
Lewis, David, Yvonne Davies, Ian A. Nieduszynski, et al.. (2000). Ultrastructural localization of sulfated and unsulfated keratan sulfate in normal and macular corneal dystrophy type I. Glycobiology. 10(3). 305–312. 28 indexed citations
19.
Lewis, David, et al.. (1980). Ameloblastoma (adamantinoma) of the mandible in the rat. Journal of Comparative Pathology. 90(3). 379–384. 13 indexed citations
20.
Bezwoda, W. R., J. S. S. Gear, D. P. Derman, et al.. (1978). Combination chemotherapy including bleomycin in the treatment of advanced Hodgkin's disease.. PubMed. 53(10). 369–73. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sumeet Ambarkhane Breakdown of academic impact, for papers by Aleš Obr Breakdown of academic impact, for papers by Gloria Iacoboni Breakdown of academic impact, for papers by Brian Hess Breakdown of academic impact, for papers by Martin Dreyling Breakdown of academic impact, for papers by Zhitao Ying Breakdown of academic impact, for papers by Ranjit Nair Breakdown of academic impact, for papers by Julien Lazarovici Breakdown of academic impact, for papers by Chaitra S. Ujjani Breakdown of academic impact, for papers by M Pfreundschuh
Rankless by CCL
2026